Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Processa Pharmaceuticals Inc (NQ: PCSA )

1.560 -0.100 (-6.02%)
Streaming Delayed Price Updated: 3:59 PM EDT, Apr 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Processa Pharmaceuticals Inc

< Previous 1 2 3 Next >
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Presents New Data from NGC-Cap Phase 1b Trial at AACR Annual Meeting
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Present at Upcoming MedInvest Conference
Via Investor Brand Network
Exposures Product Safety
TinyGemsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Present at Upcoming MedInvest Conference
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Participation at American Association for Cancer Research Annual Meeting
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Present at 2024 BIO CEO & Investor Conference
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Closes on $7M Public Offering
Via Investor Brand Network
Exposures Product Safety
Nasdaq Stocks Above $2 to Watch Now! LVTX, INBS, IKT, PCSA, DYAI
Via AB Newswire
Topics Retirement
Exposures Pension
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Releases Pricing Information for $7M Public Offering
Via Investor Brand Network
Exposures Product Safety
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
From Processa Pharmaceuticals, Inc.
Via GlobeNewswire
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Completes Phase 1b Safety Evaluation of NGC-Cap
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Plans to Expand NGC-Cap Program into Advanced or Metastatic Breast Cancer
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces 1-for-20 Reverse Stock Split
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Participation in Upcoming Biotech Showcase 2024
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Provides Interim Analysis from Phase 1b NGC-Cap Trial
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Gains Helpful Guidance on Overall Design of NGC-Cap Phase 2 Study
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Participation in December MedInvest Oncology Investor Conference
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Releases Shareholder Letter
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Reports Unexpected Passing of Board Member
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Present at Upcoming Orphan Drugs and Rare Diseases Global Congress
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Creates Advisory Board, Names Renowned Experts as Members
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Participation at Upcoming ThinkEquity Conference
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Participate at Upcoming H.C. Wainwright Global Investment Conference
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Shares Encouraging Results on Potential Cancer Treatment Approach
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Participate at Upcoming Sidoti & Co. Micro Cap Virtual Conference
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces New Stage of Corporate Leadership
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Present at MedInvest Oncology Conference
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Conduct NGC-Cap Trial Based on FDA Guidance and Project Optimus Oncology Initiative
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Report on Gastroparesis Results at Annual Digestive Disease Meeting
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Releases FY 2022 Financials, Corporate Update
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Schedules Conference Call/Webinar to Review FY 2022 Results, Discuss Corporate Updates
Via Investor Brand Network
Exposures Product Safety
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.